Kaneda H , Yoshida T , Okamoto I .

Figure 1. (A and B) Strategies to overcome acquired epidermal growth-factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance in non-small-cell lung cancer (NSCLC). (A) The T790M secondary mutation in exon 20 of EGFR is present in 50%–70% of NSCLC patients who acquire resistance to EGFR-TKIs, such as gefitinib or erlotinib. In such patients, gefitinib is not able to compete with adenosine triphosphate (ATP) for binding to the ATP-binding cleft of EGFR because of an increased affinity of this site for ATP. Treatment with irreversible EGFR-TKIs or EGFR-TKIs selective for EGFR harboring T790M is thus thought to represent a potential approach to overcome the resistance conferred by this mutation. (B) Amplification of MET is apparent in 5%–15% of NSCLC patients who acquire EGFR-TKI resistance. In this situation, MET signaling through ErbB3 (HER3) is activated in addition to EGFR signaling, with the result that both gefitinib and a MET inhibitor (such as PHA665752) are necessary to overcome the resistance conferred by MET amplification. The combination of inhibitors that block molecules that function downstream of both EGFR and MET, such as a phosphoinositide 3-kinase (PI3K) inhibitor combined with an MEK (ERK kinase) inhibitor, might also be an alternative approach to overcome the resistance induced by MET amplification.

Arcila, Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. 2011, Pubmed

Arcila, Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. 2011, Pubmed
Azzoli, [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. 2010, Pubmed
Balak, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. 2006, Pubmed
Branford, High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. 2002, Pubmed
Camidge, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. 2012, Pubmed
Ceccon, Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. 2013, Pubmed
Choi, Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. 2008, Pubmed
Christensen, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. 2007, Pubmed
Cortes-Funes, Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. 2005, Pubmed
D'Addario, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010, Pubmed
Engelman, PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. 2007, Pubmed
Engelman, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 2007, Pubmed
Fukuoka, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). 2011, Pubmed
Gonzales, Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. 2008, Pubmed
Gridelli, Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. 2011, Pubmed
Guix, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. 2008, Pubmed
Hall, Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. 2000, Pubmed
Han, Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. 2006, Pubmed
Han, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. 2012, Pubmed
Inoue, Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. 2006, Pubmed
Inoue, Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). 2013, Pubmed
Jackman, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. 2009, Pubmed
Katayama, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. 2011, Pubmed , Echinobase
Kobayashi, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. 2005, Pubmed
Kosaka, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. 2006, Pubmed
Kumar, Structure and clinical relevance of the epidermal growth factor receptor in human cancer. 2008, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Li, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. 2008, Pubmed
Lin, Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. 2009, Pubmed , Echinobase
Lovly, Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. 2011, Pubmed
Lynch, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004, Pubmed
Maemondo, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. 2010, Pubmed
Maheswaran, Detection of mutations in EGFR in circulating lung-cancer cells. 2008, Pubmed
Mano, Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. 2008, Pubmed , Echinobase
Mino-Kenudson, A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. 2010, Pubmed
Mitsudomi, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. 2005, Pubmed
Mitsudomi, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. 2010, Pubmed
Mok, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. 2009, Pubmed
Morgillo, Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. 2006, Pubmed
Morgillo, Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. 2007, Pubmed
Morinaga, Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. 2007, Pubmed
Morita, Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. 2009, Pubmed
Nagai, Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. 2005, Pubmed
Oizumi, Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. 2012, Pubmed
Okabe, Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. 2009, Pubmed
Paez, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004, Pubmed
Palmer, Anaplastic lymphoma kinase: signalling in development and disease. 2009, Pubmed , Echinobase
Pao, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 2004, Pubmed
Pao, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, Pubmed
Regales, Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. 2009, Pubmed
Rodig, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. 2009, Pubmed
Rosell, Screening for epidermal growth factor receptor mutations in lung cancer. 2009, Pubmed
Rosell, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012, Pubmed
Sakamoto, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. 2011, Pubmed
Sequist, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. 2008, Pubmed
Sequist, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. 2011, Pubmed
Shimamura, Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. 2008, Pubmed
Siegel, Cancer statistics, 2012. 2012, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Solomon, ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. 2009, Pubmed , Echinobase
Sos, Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. 2010, Pubmed
Sos, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. 2009, Pubmed
Su, Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. 2012, Pubmed
Suda, Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. 2011, Pubmed
Sugawara, Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. 2012, Pubmed
Sugio, Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. 2009, Pubmed
Sunaga, Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. 2007, Pubmed
Sutani, Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. 2006, Pubmed
Takano, EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. 2008, Pubmed
Takeuchi, Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. 2008, Pubmed
Takeuchi, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009, Pubmed
Takezawa, Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. 2010, Pubmed
Tamborini, A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. 2004, Pubmed
Tamura, Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). 2008, Pubmed
Tiseo, EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. 2011, Pubmed
Toyooka, EGFR mutation and response of lung cancer to gefitinib. 2005, Pubmed
Uramoto, Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. 2011, Pubmed
Wong, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 2009, Pubmed , Echinobase
Yamasaki, Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. 2007, Pubmed
Yano, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. 2008, Pubmed
Yao, TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. 2010, Pubmed
Yoshida, Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. 2007, Pubmed
Yoshida, Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. 2010, Pubmed
Yoshida, Comprehensive histologic analysis of ALK-rearranged lung carcinomas. 2011, Pubmed
Yun, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. 2008, Pubmed
Zakowski, EGFR mutations in small-cell lung cancers in patients who have never smoked. 2006, Pubmed
Zhou, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. 2011, Pubmed
Zhou, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. 2009, Pubmed
Zou, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. 2007, Pubmed